Exhibitors Search
Gencellmed Inc.
Booth no.
H50/P70
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| |
|
Address
|
|75 Nowon-ro, Nowon-gu, Seoul, Republic of Korea |
|
Tel
|
|+82-2-974-5858 |
|
Exhibits
|
| HSV SMART™ Platform-Based EpCAM-Targeted Oncolytic HSV GCM-101 and Gene Therapies |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup |
Exhibitor Information
Gencellmed Inc. is a biotechnology company developing HSV-based oncolytic viruses and gene therapies. Founded on research from the Korea Institute of Radiological & Medical Sciences (KIRAMS), the company is advancing pipelines in oncology, skin regeneration, and ophthalmic diseases. Its lead asset, GCM-101, is a targeted oncolytic virus for EpCAM-positive ovarian cancer and peritoneal metastatic solid tumors, designed to selectively infect and lyse tumor cells while inducing anti-tumor immune responses. GCM-101 was selected for both KDDF lead and candidate development programs and is currently in preclinical development with IND preparation underway.
Gencellmed has filed 21 patent applications and secured 16 patents in Korea and overseas, and is conducting government-funded R&D programs through 2029. The company is seeking partnerships for licensing, co-development, investment, and CRO/CDMO collaboration.
Gencellmed has filed 21 patent applications and secured 16 patents in Korea and overseas, and is conducting government-funded R&D programs through 2029. The company is seeking partnerships for licensing, co-development, investment, and CRO/CDMO collaboration.
Exhibit Description
Gencellmed Inc. is developing oncolytic viruses and gene therapies based on its SMART™ platform, which re-engineers the HSV cell-entry mechanism to enable selective infection and gene delivery to specific target cells.
Its lead asset, GCM-101, is a targeted oncolytic virus under development for EpCAM-positive ovarian cancer and peritoneal metastatic solid tumors, and is currently in preclinical development with IND preparation underway. Gencellmed is also expanding its pipeline with replication-defective HSV gene therapy candidates for skin regeneration and ophthalmic diseases.
The SMART™ platform is designed to support a broad range of targets and therapeutic genes, with commercialization pursued through licensing, co-development, and global partnerships.
Its lead asset, GCM-101, is a targeted oncolytic virus under development for EpCAM-positive ovarian cancer and peritoneal metastatic solid tumors, and is currently in preclinical development with IND preparation underway. Gencellmed is also expanding its pipeline with replication-defective HSV gene therapy candidates for skin regeneration and ophthalmic diseases.
The SMART™ platform is designed to support a broad range of targets and therapeutic genes, with commercialization pursued through licensing, co-development, and global partnerships.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : SMART™ Platform (Synthetic & Multi-Antigen Retargeting Technology)SMART™ (Synthetic & Multi-Antigen Retargeting Technology) is Gencellmed’s core HSV platform that re-engineers viral cell entry to enable selective infection and gene delivery to cells expressing specific targets. By restricting natural HSV entry and introducing target receptor-based retargeting, the platform is designed to enhance target-cell selectivity. SMART™ can be applied to both oncolytic viruses and replication-defective HSV gene therapies and supports combinations of different targets and therapeutic genes across oncology, skin regeneration, and ophthalmic diseases. The platform is currently applied to GCM-101 and additional gene therapy pipelines, with licensing, co-development, and global partnerships being pursued.
-
Product Name : GCM-101GCM-101 is a targeted oncolytic HSV candidate for EpCAM-positive ovarian cancer and peritoneal metastatic solid tumors. It is designed for intraperitoneal (IP) administration and selective infection and lysis of EpCAM-expressing tumor cells. GCM-101 expresses IL-12 and FLT3L to promote anti-tumor immune responses, while PH20 degrades hyaluronic acid in the tumor stroma to enhance viral and immune-cell penetration. Through these mechanisms, GCM-101 combines direct tumor killing, immune activation, and tumor microenvironment modulation. The program is currently in preclinical development, with IND-enabling activities including CMC, manufacturing process development, and GLP toxicology preparation underway. GenCellMed plans to pursue licensing, co-development, and global partnerships.
KYUNGYON EXHIBITION CORP.
